Shingo Kanda

No ORCID on file · 3 papers in corpus
rct 2020
A multicenter, randomized, placebo-controlled, double-blind, comparative study of dienogest at 1 mg/day in patients with primary and secondary dysmenorrhea
Fertility and sterility ·doi:10.1016/j.fertnstert.2019.11.010

OBJECTIVE: To evaluate the efficacy and safety of dienogest (DNG), a progestational 19-norsteroid, in patients with primary and secondary dysmenorrhea. DESIGN: Phase III, randomized, double-blind, multicenter, placebo-controlled study. SE…

nonrandomized-trial 2020
Long-term use of dienogest for the treatment of primary and secondary dysmenorrhea
Journal of Obstetrics and Gynaecology Research ·doi:10.1111/jog.14209

AIM: To investigate the safety and efficacy of dienogest (DNG), a progestational 19-norsteroid, administered for 52 weeks in patients with primary and secondary dysmenorrhea. METHODS: A total of 147 patients with dysmenorrhea received 1 mg…

rct 2019
Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study
Fertility and sterility ·doi:10.1016/j.fertnstert.2019.09.014

OBJECTIVE: To evaluate the efficacy, safety, and clinically recommended dose of dienogest (DNG; 0.5 mg/d, 1 mg/d, and 2 mg/d) in the treatment of primary dysmenorrhea. DESIGN: A phase II, randomized, double-blind, multicenter, placebo-cont…